Formoterol vs. Vilanterol

Attribute	Formoterol	Vilanterol
Drug class	Beta2-agonist	Beta2-agonist
Indication	Asthma, COPD	Asthma, COPD
Route of administration	Inhalation	Inhalation
Duration of action	12 hours	24 hours
Brand name	Foradil	Breo Ellipta

Introduction

Formoterol and Vilanterol are both long-acting beta agonists (LABAs) that are commonly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). While they belong to the same class of medications, there are some differences in their attributes that may make one more suitable than the other for certain patients. In this article, we will compare the key attributes of Formoterol and Vilanterol to help healthcare providers make informed decisions when prescribing these medications.

Mechanism of Action

Formoterol and Vilanterol both work by stimulating beta-2 adrenergic receptors in the lungs, which leads to relaxation of the smooth muscles in the airways. This results in bronchodilation, making it easier for the patient to breathe. However, Formoterol has a faster onset of action compared to Vilanterol, with effects lasting for up to 12 hours. On the other hand, Vilanterol has a longer duration of action, with effects lasting for up to 24 hours.

Indications

Both Formoterol and Vilanterol are indicated for the maintenance treatment of asthma and COPD. They are typically used in combination with an inhaled corticosteroid as part of a long-term treatment plan. However, Formoterol is also approved for use as a rescue inhaler in patients with asthma, providing quick relief of symptoms during an asthma attack. Vilanterol, on the other hand, is not approved for use as a rescue inhaler and should not be used to treat acute symptoms.

Side Effects

Common side effects of Formoterol and Vilanterol include headache, tremor, and palpitations. However, Formoterol may also cause a faster heart rate and increased blood pressure in some patients. On the other hand, Vilanterol is associated with a higher risk of pneumonia compared to Formoterol. Patients should be monitored closely for any signs of respiratory infections while taking Vilanterol.

Drug Interactions

Formoterol and Vilanterol may interact with other medications, so it is important for healthcare providers to review the patient's medication list before prescribing these LABAs. Formoterol should not be used concomitantly with other long-acting beta agonists, as this may increase the risk of adverse effects. Vilanterol, on the other hand, should not be used with other LABAs or similar medications, as this may also increase the risk of side effects.

Dosing and Administration

Formoterol is typically administered as an inhalation powder or aerosol, with dosing ranging from 6 to 24 micrograms twice daily. It is important for patients to follow the prescribed dosing schedule and not exceed the recommended dose. Vilanterol is also available as an inhalation powder, with a recommended dose of 25 micrograms once daily. Patients should be instructed on how to use the inhaler properly to ensure optimal delivery of the medication.

Cost

When comparing the cost of Formoterol and Vilanterol, it is important to consider factors such as insurance coverage and generic availability. Formoterol is available as a generic medication, which may make it more affordable for some patients. Vilanterol, on the other hand, is only available as a brand-name medication, which may be more expensive. Patients should discuss their options with their healthcare provider to determine the most cost-effective treatment plan.

Conclusion

Formoterol and Vilanterol are both effective medications for the treatment of asthma and COPD, but they have some differences in terms of onset of action, duration of action, side effects, and cost. Healthcare providers should consider these factors when prescribing these medications to ensure that patients receive the most appropriate treatment for their condition. By understanding the attributes of Formoterol and Vilanterol, healthcare providers can make informed decisions that optimize patient outcomes.